US EditionShares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
Novo Nordisk gains a first-mover edge with the FDA-approved oral GLP-1 obesity pill, priced at $149 per month, boosting investor confidence after a challenging year.
- Shares jumped 6% Monday after the U.S. Food and Drug Administration approved oral semaglutide, branded as a Wegovy pill, making it the first oral GLP-1 therapy cleared for obesity.
- After a turbulent year, Novo Nordisk A/S gains a first-mover advantage over Eli Lilly, Pfizer, and others despite board drama, supply shortages, and market-share losses to compounded products and competitors.
- In early January the 1.5 milligram starting dose will be available in pharmacies and select telehealth providers for $149 per month, and cash-paying patients can buy it via TrumpRx under last month's deal.
- Analysts at BMO Capital Markets said the approval lifted investor sentiment but warned it does not resolve Novo Nordisk's longer-term competitive challenges, maintaining a Market Perform rating with a $46 price target.
- Growing oral-GLP1 competition from Structure Therapeutics and Metsera means Eli Lilly's orforglipron is expected in 2026, and analysts flagged a food effect limitation with 2026 clinical and sales catalysts pivotal.
17 Articles
17 Articles
Novo Nordisk has achieved green light to sell in the United States a pill version of his successful Wegovy obesity injection, a crucial step in his effort to defend his market share against his rival Eli Lilly. Novo will start selling the pill on the American market early in January, while Eli Lilly has not yet received approval for a similar pill. The Danish company’s action shoots at 7.5% on the Copenhagen Stock Exchange. Continue reading
Novo Nordisk's shares rose more than 7% this Tuesday, after the Danish pharmaceutical company obtained approval from the U.S. Food and Drug Administration (FDA) for its LPG-1 pill, It is the first in the world of its kind to receive regulatory approval. The authorization gives Novo Nordisk an initial advantage over its American rival Eli Lilly, who also develops an oral drug of the same kind and who has already submitted his application for appr…
European Stocks Hit Record Amidst Healthcare Surge
European Stocks Hit Record Amidst Healthcare Surge European stocks experienced a brief surge to unprecedented levels on Tuesday, driven largely by the robust performance of the healthcare sector. This rally was spearheaded by Novo Nordisk, whose shares soared 7.6% following the U.S. approval of its innovative weight-loss pill.The Danish pharmaceutical giant now appears to have a competitive edge over its American rival Eli Lilly in the burgeonin…
The Danish laboratory benefits from a green light from the US authorities. European stock markets opened without clear direction Tuesday, in...
There has been little good news for Novo Nordisk in 2025, but on one of the last trading days of the year, the price of the pharmaceutical stock increases considerably. On Tuesday, Novo shares are trading 5.7 percent...
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
